Drug Discovery World

MAY 18, 2023

A clinical trial of an experimental universal influenza vaccine developed by researchers at the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC) has begun enrolling volunteers at Duke University in Durham, North Carolina.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

Pharmaceutical Technology

MAY 22, 2023

It can suppress Th2 immune responses by binding to IL-17RB on Type 2 innate lymphoid cells (ILC2s). This blocks a cascade of responses that are induced by interleukin-25 (IL-25), a critical cytokine which is classified as ‘alarmin’.

Immune Response 273

Immune Response Clinical Trials Clinical Trials Antibody 273

XTalks

NOVEMBER 6, 2020

Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. The first healthy volunteer was dosed with the vaccine in Australia as part of the bacTRL-Spike COVID-19 Phase I clinical trial. COVID-19 Clinical Trials.

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

pharmaphorum

SEPTEMBER 7, 2020

A trial of Russia’s Sputnik V coronavirus vaccine has shown the jab produces an immune response, although the study was too small to produce conclusive findings, particularly on safety. Preclinical and clinical studies have made it possible to provisionally approve the vaccine under the current Russian coronavirus regulations.

Immune Response 87

Immune Response Vaccination Vaccine Trials 87

The Pharma Data

DECEMBER 23, 2020

In the context of a substantial amount of COVID-19-related research and the launch of numerous clinical trials, the French government created this steering committee to prioritize and accelerate high potential clinical trials. This Phase IIa trial follows a preliminary study conducted by Prof.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Research 52

Scienmag

JANUARY 14, 2021

14, 2021) – Researchers at Baylor College of Medicine have discovered how therapeutics targeting RNA splicing can activate antiviral immune pathways in triple negative breast cancers (TNBC) to trigger tumor cell death and signal the body’s immune response. HOUSTON – (Jan.

Immune Response 41

Immune Response RNA Medicine Research 41

Medical Xpress

JANUARY 30, 2023

A newly published paper in The Lancet shows that an experimental vaccine against Marburg virus (MARV) was safe and induced an immune response in a small, first-in-human clinical trial.

Vaccination 104

Vaccination Vaccine Immune Response Allergies 104

The Pharma Data

NOVEMBER 10, 2020

Canadian biopharmaceutical company Medicago has announced that its investigational COVID-19 vaccine generated “significant antibody and cellular immune responses” after two doses in all subjects in an early-stage clinical trial. Martin Berman-Gorvine. Source link.

Immune Response 40

Immune Response Vaccination Vaccine Clinical Trials 40

Pharmaceutical Technology

MAY 19, 2023

OncoResponse has secured a $13m grant from the Cancer Prevention and Research Institute of Texas (CPRIT) and raised an additional $14m in funding from investors for advancing OR502 to investigational new drug (IND) and clinical trials. It is planned to enter clinical studies this year.

Immune Response 130

Immune Response Clinical Trials Clinical Trials Antibody 130

Drug Discovery World

JANUARY 17, 2023

Genoscience Pharma, a clinical-stage biotech company developing lysosomotropic drug candidates for the treatment of cancer, fibrosis and auto-immune diseases through autophagy modulation has launched the ABE-LIVER study, along with trial sponsor Grenoble University Hospital. . The trial . Official comments .

Clinical Trials 52

Clinical Trials Clinical Trials Trials Development 52

The Pharma Data

MARCH 31, 2022

A Phase 2 clinical trial evaluating various additional COVID-19 booster shots has begun enrolling adult participants in the United States. “This trial will help us understand if we can use prototype and variant vaccines alone or together to shift immune responses to cover existing and emerging COVID-19 variants.”

Clinical Trials 52

Clinical Trials Clinical Trials Trials Immune Response 52

Pharmaceutical Technology

JUNE 23, 2022

It was based on findings from seven double-blind, randomised, clinical trials that evaluated the safety, tolerability and immunogenicity of the vaccine in infants, children and adolescents.

Vaccination 147

Vaccination Vaccine Immune Response Clinical Trials 147

Drug Discovery World

FEBRUARY 28, 2024

Lu Rahman selects some of the year’s interesting and noteworthy advances in cancer research drug discovery and development. In the UK, according to Cancer Research UK, around 167,000 people die from cancer in the UK each year. Research into new drugs and therapeutics is on-going and is helping drive mortality rates down.

Development 64

Development Research Drugs Antibody 64

Drug Discovery World

APRIL 3, 2023

A team of researchers at the Keck School of Medicine of University of Southern California (USC) have found a drug with the potential for curbing painful hyperinflammation from osteoarthritis, according to results of an animal study. In trying to fix the problem, the immune system causes even more damage,” said Evseenko.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Drugs 52

Pfizer

FEBRUARY 16, 2023

These study participants, representing approximately half of the total recruited participants in the trial, are being discontinued following violations of Good Clinical Practice (GCP) at certain clinical trial sites run by a third-party clinical trial site operator.

Clinical Trials 76

Clinical Trials Clinical Trials Vaccination Vaccine 76

Pharmaceutical Technology

OCTOBER 14, 2022

The mRNA-4157/V940 has been designed to stimulate an immune response by producing T-cell responses depending on the mutational signature of a patient's tumour.

Vaccination 289

Vaccination Vaccine Development Immune Response 289

Pharmaceutical Technology

MAY 10, 2023

XinThera’s therapy targeting MK2 is expected to enter clinical trials later in 2023. By adding an additional pipeline targeting oncology and inflammation diseases, the company expects that the deal will complement its existing clinical development priorities.

Immune Response 130

Immune Response DNA Clinical Trials Clinical Trials 130

Pharmaceutical Technology

APRIL 28, 2023

Therini Bio will use part of the funds to advance its potential first-in-class investigational antibody, THN391, into clinical trials. THN391 binds the inflammation-driving component of fibrin, known for activating the immune responses in neurodegenerative and ophthalmologic diseases.

Development 130

Development Immune Response Clinical Trials Clinical Trials 130

The Pharma Data

DECEMBER 20, 2020

UK drug developer Scancell said it has chosen a COVID-19 vaccine candidate, SN14, from more than a dozen potential products to advance to a clinical trial. . In October, Scancell signed a manufacturing deal for SN14 with Cobra Biologics, a Cognate BioServices subsidiary, ahead of a planned phase 1 trial in 2021. Source link.

Clinical Trials 52

Clinical Trials Clinical Trials Pharma Companies Vaccination 52

STAT News

DECEMBER 23, 2022

In a clinical trial, 60% of patients with follicular lymphoma treated with Lunsumio achieved a complete response. The most common side effect was an overactive immune response called cytokine release syndrome, reported by 39% of patients. Continue to STAT+ to read the full story…

FDA Approval 98

FDA Approval Immune Response Drugs Research 98

XTalks

DECEMBER 29, 2023

Reese, executive vice president of Research and Development at Amgen, in the company’s press release. Tarlatamab is an investigational drug currently undergoing clinical trials to assess its efficacy in patients with two distinct types of neuroendocrine cancer: SCLC and neuroendocrine prostate cancer (NEPC).

Clinical Trials 119

Clinical Trials Clinical Trials FDA Approval Trials 119

The Pharma Data

MARCH 11, 2021

Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. The Companies expect interim results from this trial in the third quarter of 2021. About the Phase 1/2 clinical trial.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

Drug Discovery World

JULY 5, 2023

Global Cancer Segment Market Manager at Agilent Technologies, recently sat down with DDW Editor Reece Armstrong to tell us about the developments in the ‘golden age’ of cancer research. MG: I am responsible for Agilent’s cancer segment. RA: What is the current state of the cancer research industry? Mark Garner, PhD.,

Research 98

Research Protein Scientist Immune Response 98

XTalks

JANUARY 20, 2021

Researchers at KU Leuven in Belgium have found a potential mechanism underlying irritable bowel syndrome (IBS) that involves activation of immune cells primed by past gastrointestinal infections. The research findings were published in the journal Nature. Related: Monitoring Patients with IBS or Kidney Failure?

Immune Response 52

Immune Response Research Allergies Protein 52

pharmaphorum

NOVEMBER 25, 2022

Rather than completely preventing infections, the aim would be to stimulate a memory immune response that could be quickly recalled and adapted to new pandemic viral strains. ” Hensley et al say they are currently designing human clinical trials of the vaccine candidate.

Vaccination 104

Vaccination Vaccine Research Immune Response 104

pharmaphorum

MAY 19, 2022

Moderna’s vaccines deliver HIV-specific antigens discovered by researchers at IAVI and Scripps Research that have already been tested in a proof-of-concept study carried out last year using an adjuvant protein vaccine approach. HVAD #HVAD2022 pic.twitter.com/KLrVRXtEAv. — Moderna (@moderna_tx) May 18, 2022.

Vaccination 145

Vaccination Vaccine Trials Immune Response 145

Pharmaceutical Technology

AUGUST 5, 2022

The scientific approach of MiroBio for immune balance restoration to treat autoimmune diseases complements the inflammation research and development works of Gilead. MB272, the lead investigational antibody of MiroBio, is a selective immune inhibitory receptor B- and T-Lymphocyte Attenuator (BTLA) agonist.

Antibody 130

Antibody Immune Response Clinical Trials Clinical Trials 130

Pharmaceutical Technology

OCTOBER 6, 2022

BioLink Life Sciences has received a contract worth $750,000 from the US Biomedical Advanced Research and Development Authority (BARDA) to develop Ramatroban for treating Covid-19 pneumonia patients in the hospital setting. Ramatroban will be analysed in a placebo-controlled, randomised Phase II/III RAMBAN-1 clinical trial.

Development 162

Development Life Science Immune Response Trials 162

Drug Discovery World

MARCH 4, 2024

In an early phase clinical trial, a combination of antibody-based medications targeting the immune system generated promising safety data and anti-tumour activity in individuals with advanced cancer. Both medications tested in the trial support immune responses against tumour cells.

Antibody 115

Antibody Immune Response Trials Clinical Trials 115

XTalks

FEBRUARY 19, 2024

In a recent study published by Weill Cornell Medicine in the Journal of Infectious Diseases , researchers have reported the potential of Moderna’s experimental mRNA vaccine in protecting adults against CMV, which could potentially also stop the transmission of the virus from mothers to their infants during pregnancy.

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

Worldwide Clinical Trials

JUNE 15, 2022

The pandemic has had a lasting impact on the ability of sites to participate in trials, particularly in the US. We’ve also seen a decrease in available research nurses, as they have had to be reassigned to COVID patients. 5 Things You Need to Know from Our Recent Gene Therapy Webinar appeared first on Worldwide Clinical Trials.

Gene Therapy 130

Gene Therapy Gene Clinical Trials Clinical Trials 130

Drug Discovery World

JULY 26, 2023

A Cancer Research UK-funded clinical trial has shown, for the first time, that a new class of antibody could benefit cancer patients whose existing treatments have stopped working. The drug, MOv18 IgE, was developed by researchers at King’s College London.

Antibody 52

Antibody Drugs Clinical Trials Clinical Trials 52

World of DTC Marketing

APRIL 11, 2021

Further scientific research into the virus and recognition that it was not like influenza A, a flu virus known to cause bronchitis, would transpire over the next 30 years. . If your body develops an immune response—the goal of vaccination—there is a possibility you may test positive on some antibody tests.

Vaccination 303

Vaccination Vaccine Clinical Trials Clinical Trials 303

Drug Discovery World

OCTOBER 7, 2022

Researchers from King’s College London and The Institute of Cancer Research, London, have performed a deep dive into the different immune markers within tumour tissue and blood samples of early breast cancer patients whose cancer failed to respond to chemotherapy given to them prior to surgery.

Research 52

Research Immune Response Gene Bioinformatics 52

pharmaphorum

FEBRUARY 25, 2021

Maryland, US-based company Altimmune is among the biotechs and research labs trying to find more convenient alternatives and believes a nasal vaccine spray that is stable at room temperature could be the answer. A nasal delivery method will also produce an immune response at the point where the virus enters the body.

Vaccination 106

Vaccination Vaccine Immune Response Trials 106

Drug Discovery World

JANUARY 10, 2023

The American Association for Cancer Research (AACR) Annual Meeting 2023 will be held April 14-19 at the Orange County Convention Center in Orlando, Florida. Clinical trials and late-breaking abstracts should be submitted by Thursday, January 12. . View the full programme here.

Immune Response 52

Immune Response Clinical Trials Clinical Trials Research 52

The Pharma Data

OCTOBER 25, 2020

German drugmaker CureVac said preclinical studies of its COVID-19 vaccine candidate, CVnCoV, showed the vaccination prompted a successful immune response. The vaccine is currently being evaluated in phase 1 and 2 human clinical trials. Source link.

Vaccination 52

Vaccination Vaccine Immune Response RNA 52